Skip to main content
NACFC 2023 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Livestream
Livestream
Ticketed Session
Ticketed Session
Recorded Session
Recorded Session
Back

PHARM
Thematic Poster Session

TPS03--Pharmacotherapy Thematic Poster Session.

Thursday, November 2, 2023
2:00 PM – 3:30 PM MST
Location:Theater C (Exhibit & Poster Hall)

The session consists of two main parts: (1) poster viewing followed by a (2) moderated discussion. It is designed to engage the authors and the audience in a discussion that ties together ideas from multiple posters in the session.

This pharmacy thematic poster session will provide an update on current pharmacy services and practices, highlight some medications used in CF, and update our knowledge of the real-world effects of elexacaftor-tezacaftor-ivacaftor (ETI). Topics will include the use of antidepressants and pancreatic enzymes in the CF population, pharmacokinetic variability of CFTR modulators, accessibility issues related to ETI, and adverse reactions to ETI along with potential management strategies.

Seating is limited to 65 seats.

Presentations:

  • 2:00 PM – 3:30 PM MST
    TPS03.1- The evolution of pharmacy services at US CFF-accredited centers: ten years later

    Speaker: Paige M. Grube, PharmD – University of Kentucky

  • 2:00 PM – 3:30 PM MST
    TPS03.2- Documentation Practices of Cystic Fibrosis (CF) Pharmacists: An Opportunity for Discipline-Wide Quality Improvement

    Speaker: Hanna Phan, PharmD (she/her/hers) – University of Michigan / Michigan Medicine

  • 2:00 PM – 3:30 PM MST
    TPS03.3- Contemporary analysis in pancreatic enzyme use in the Nova Scotian Cystic Fibrosis population

    Speaker: Adelaide von Kursell, MSc (she/her/hers) – Dalhousie University

  • 2:00 PM – 3:30 PM MST
    TPS03.4- Selective serotonin reuptake inhibitor response in persons with cystic fibrosis

    Speaker: Emma M. Tillman, PharmD,PhD (she/her/hers) – Indiana Unversity

  • 2:00 PM – 3:30 PM MST
    TPS03.5- Outcomes Of Patients With Intermittent Versus Continuous Access To CFTR Modulator Therapy in Turkey

    Speaker: Yasemin Gokdemir, MD (she/her/hers) – Marmara University Medical Faculty

  • 2:00 PM – 3:30 PM MST
    TPS03.6- Pharmacokinetic variability of CFTR modulators from standard and alternative regimens

    Speaker: Jennifer S. Guimbellot, MD, PhD – University of Alabama at Birmingham

  • 2:00 PM – 3:30 PM MST
    TPS03.7- Elexacaftor-Tezacaftor-Ivacaftor associated rash management at a large pediatric cystic fibrosis center: a multidisciplinary approach

    Speaker: Jenna M. Faircloth, PharmD – Texas Children's Hospital

  • 2:00 PM – 3:30 PM MST
    TPS03.8- Evaluation of the adverse effects of elexacaftor/tezacaftor/ivacaftor in pediatric cystic fibrosis patients age 6-11 years

    Speaker: Bharathi Ravikumar, PharmD (she/her/hers) – Riley Hospital for Children at IU Health

  • 2:00 PM – 3:30 PM MST
    TPS03.9- Analysis of cholesterol levels after initiation of elexacaftor/tezacaftor/ivacaftor

    Speaker: Kevin P. Lonabaugh, PharmD, BCACP, BCPPS (he/him/his) – University of Virginia (UVA) Health

  • 2:00 PM – 3:30 PM MST
    TPS03.10- Alopecia in children and adults with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor

    Speaker: Kimberly G. Stephenson, MS, RD, CSP, CACFD (she/her/hers) – University of North Carolina Health